PL3419622T3 - Leczenie neurodegeneracyjnej choroby oczu przy użyciu pridopidyny - Google Patents

Leczenie neurodegeneracyjnej choroby oczu przy użyciu pridopidyny

Info

Publication number
PL3419622T3
PL3419622T3 PL17757261.7T PL17757261T PL3419622T3 PL 3419622 T3 PL3419622 T3 PL 3419622T3 PL 17757261 T PL17757261 T PL 17757261T PL 3419622 T3 PL3419622 T3 PL 3419622T3
Authority
PL
Poland
Prior art keywords
pridopidine
treatment
eye disease
neurodegenerative eye
neurodegenerative
Prior art date
Application number
PL17757261.7T
Other languages
English (en)
Inventor
Hermann Kurt Russ
Michal Geva
Ralph Laufer
Aric ORBACH
Original Assignee
Prilenia Neurotherapeutics Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prilenia Neurotherapeutics Ltd. filed Critical Prilenia Neurotherapeutics Ltd.
Publication of PL3419622T3 publication Critical patent/PL3419622T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/451Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicinal Preparation (AREA)
PL17757261.7T 2016-02-24 2017-02-24 Leczenie neurodegeneracyjnej choroby oczu przy użyciu pridopidyny PL3419622T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662299290P 2016-02-24 2016-02-24
PCT/US2017/019266 WO2017147366A1 (en) 2016-02-24 2017-02-24 Treatment of neurodegenerative eye disease using pridopidine

Publications (1)

Publication Number Publication Date
PL3419622T3 true PL3419622T3 (pl) 2024-07-08

Family

ID=59686581

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17757261.7T PL3419622T3 (pl) 2016-02-24 2017-02-24 Leczenie neurodegeneracyjnej choroby oczu przy użyciu pridopidyny

Country Status (10)

Country Link
US (1) US11738012B2 (pl)
EP (1) EP3419622B1 (pl)
JP (1) JP7034488B2 (pl)
AU (1) AU2017223838B2 (pl)
CA (1) CA3015512C (pl)
DK (1) DK3419622T3 (pl)
ES (1) ES2979123T3 (pl)
HU (1) HUE066769T2 (pl)
PL (1) PL3419622T3 (pl)
WO (1) WO2017147366A1 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ608120A (en) 2010-09-03 2014-12-24 Ivax Int Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
US20220062255A1 (en) * 2016-02-24 2022-03-03 Prilenia Neurotherapeutics Ltd. Treatment of neurodegenerative eye disease using pridopidine
CN109923102B (zh) 2016-08-24 2022-11-15 普瑞尼亚神经治疗有限公司 普利多匹定用于治疗功能下降的用途
JP7278210B2 (ja) 2016-08-24 2023-05-19 プリレニア ニューロセラピューティクス リミテッド ジストニアを治療するためのプリドピジンの使用
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
EP3678664A1 (en) 2017-09-08 2020-07-15 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
US12357624B2 (en) 2019-02-04 2025-07-15 Prilenia Neurotherapeutics Ltd. Low dose pridopidine for Parkinson's Disease and other diseases associated with parkinsonism
EP3937937A4 (en) * 2019-03-15 2022-11-23 Prilenia Neurotherapeutics Ltd. TREATMENT OF MITOCHONDRIAL ASSOCIATED DISEASES AND DISORDERS, INCLUDING SYMPTOMS THEREOF; USING PRIDOPIDINE
EP4415714A4 (en) * 2021-10-11 2025-10-15 Prilenia Neurotherapeutics Ltd PRIDOPIDINE AND ANALOGUES THEREOF FOR THE TREATMENT OF NEURODEGENERATIVE EYE DISEASE

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
IL134241A (en) * 2000-01-27 2006-06-11 Finetech Pharmaceutical Ltd Process for the preparation of latanoprost
WO2004103263A2 (en) * 2003-05-22 2004-12-02 Yeda Research And Development Co. Ltd. Dopamine and agonists and antagonists thereof for treatment of neurodegenerative diseases
SE0401465D0 (sv) 2004-06-08 2004-06-08 Carlsson A Research Ab New substituted piperdines as modulators of dopamine neurotransmission
CN101056854B (zh) 2004-10-13 2013-06-05 Nsab神经研究瑞典公司分公司 合成4-(3-甲磺酰基苯基)-1-n-丙基-哌啶的方法
MX2009011020A (es) 2007-04-12 2009-10-30 Nsab Af Neurosearch Sweden Ab Derivados de n-oxido y/o di-n-oxido de los estabilizadores/modulad ores del receptor de dopamina que exhiben perfiles mejorados de los efectos secundarios cardiovasculares.
CA2688439A1 (en) * 2007-05-31 2008-12-11 Joseph Weinstock Treatment of age-related macular degeneration
AU2008296908B2 (en) 2007-09-05 2014-01-09 Teva Pharmaceutical Industries, Ltd. Method of treating glaucoma using rasagiline
US20110206782A1 (en) * 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
NZ608120A (en) 2010-09-03 2014-12-24 Ivax Int Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
CN103958469B (zh) 2011-09-07 2016-04-20 梯瓦制药国际有限责任公司 一种新的普利多匹定盐酸盐多晶型形态
UY34503A (es) 2011-12-08 2013-07-31 Ivax Int Gmbh ?sal de bromhidrato de pridopidina?
KR20150013476A (ko) 2012-04-04 2015-02-05 아이백스 인터내셔널 게엠베하 조합요법용 약학적 조성물
CN104768545A (zh) * 2012-09-27 2015-07-08 泰华制药工业有限公司 雷沙吉兰和普多比啶组合以治疗神经退化性病症,尤其亨廷顿氏病
PL3010506T3 (pl) 2013-06-21 2021-11-02 Prilenia Neurotherapeutics Ltd. Pridopidyna w leczeniu choroby huntingtona
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
HUE058288T2 (hu) * 2014-01-22 2022-07-28 Prilenia Neurotherapeutics Ltd Pridopidin módosított hatóanyag-leadású készítményei
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
MX2017008136A (es) 2014-12-22 2018-03-06 Teva Pharmaceuticals Int Gmbh Sal de l-tartrato de pridopidina.
WO2016138135A1 (en) 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease
EP3854785A1 (en) * 2015-02-25 2021-07-28 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat depression or anxiety
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
WO2017015615A1 (en) 2015-07-22 2017-01-26 Teva Pharmaceuticals International Gmbh Pridopidine base formulations and their use
KR20200031446A (ko) 2018-09-14 2020-03-24 삼성전자주식회사 무선 통신 시스템에서 pdcch 모니터링 방법 및 장치

Also Published As

Publication number Publication date
US20190046516A1 (en) 2019-02-14
JP7034488B2 (ja) 2022-03-14
EP3419622A4 (en) 2019-07-10
EP3419622B1 (en) 2024-03-06
DK3419622T3 (da) 2024-06-03
ES2979123T3 (es) 2024-09-24
CA3015512C (en) 2024-01-16
JP2019507758A (ja) 2019-03-22
US11738012B2 (en) 2023-08-29
WO2017147366A1 (en) 2017-08-31
AU2017223838A1 (en) 2018-09-06
CA3015512A1 (en) 2017-08-31
HUE066769T2 (hu) 2024-09-28
EP3419622A1 (en) 2019-01-02
AU2017223838B2 (en) 2022-09-29

Similar Documents

Publication Publication Date Title
HRP20190117T1 (hr) iRNK TERAPIJA ZA LIJEČENJE BOLESTI OKA
PL3419622T3 (pl) Leczenie neurodegeneracyjnej choroby oczu przy użyciu pridopidyny
ZA201807084B (en) Methods of treatment of cholestatic diseases
PT3212233T (pt) Terapia combinada para o tratamento de doenças
IL255423A0 (en) Methods for treating neurodegenerative disease
IL269106A (en) Methods for the treatment of neurodegenerative diseases
IL247085A0 (en) Methods for treating Alzheimer's disease
ZA201903003B (en) Treatment of neurological diseases
IL267229A (en) Methods of treating ocular disorders
IL246999A0 (en) Methods for treating Alzheimer's disease
GB201608046D0 (en) Treatment of complement-mediated disorders
GB201516905D0 (en) Treatment of Neurodegenerative diseases
EP3157631A4 (en) Neurodegenerative disease treatment
GB201412578D0 (en) Treatment of neurological diseases
EP3145532A4 (en) Individualized treatment of eye disease
GB201607388D0 (en) Treatment of impulsivity-related disorders
GB201714307D0 (en) Treatment of neurodegenerative diseases
EP3474876A4 (en) TREATMENT OF MORBUS CANAVAN
IL263837A (en) Treatment of ocular disease
GB201411616D0 (en) Diagnosis and treatment of neurodegenerative disorders
GB201714311D0 (en) Treatment of neurodegenerative diseases
GB201714303D0 (en) Treatment of neurodegenerative diseases
GB201604359D0 (en) Treatment of tissue disorders
SI3903774T1 (sl) N,N-bis-2-merkaptoetil izoftalamid za zdravljenje nevrodegenerativnih bolezni
GB201610938D0 (en) Treatment of ocular disease